Vanguard Group Inc. Acquires 788,499 Shares of Danaher Corporation $DHR

Vanguard Group Inc. increased its holdings in shares of Danaher Corporation (NYSE:DHR) by 1.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 60,769,587 shares of the conglomerate’s stock after purchasing an additional 788,499 shares during the period. Vanguard Group Inc. owned about 0.08% of Danaher worth $12,004,424,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after buying an additional 612,154 shares during the period. Geode Capital Management LLC boosted its stake in Danaher by 0.6% in the 2nd quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock worth $2,697,800,000 after purchasing an additional 81,670 shares during the period. Generation Investment Management LLP increased its holdings in Danaher by 56.2% during the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock worth $980,914,000 after purchasing an additional 1,787,522 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Danaher by 4.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock worth $867,168,000 after buying an additional 163,332 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Teri List sold 2,778 shares of Danaher stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 29,728 shares of company stock valued at $6,448,990 in the last quarter. 11.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

DHR has been the topic of several research reports. Rothschild & Co Redburn restated a “neutral” rating and issued a $220.00 target price (down previously from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Guggenheim restated a “buy” rating and set a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Bank of America lowered their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Wells Fargo & Company restated a “positive” rating on shares of Danaher in a research note on Thursday, October 23rd. Finally, TD Cowen lifted their target price on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $243.39.

Danaher Stock Down 0.4%

Danaher stock opened at $220.41 on Tuesday. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The firm has a market capitalization of $155.69 billion, a PE ratio of 45.45, a P/E/G ratio of 3.28 and a beta of 0.81. The company’s 50-day moving average is $206.07 and its 200-day moving average is $201.28. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.71 earnings per share. Sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio is 26.39%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.